Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial
- PMID: 22848006
- DOI: 10.1530/EJE-12-0525
Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial
Erratum in
-
Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnea: a randomized placebo-controlled trial.Eur J Endocrinol. 2015 Nov;173(5):X3. doi: 10.1530/EJE-12-0525e. Eur J Endocrinol. 2015. PMID: 26516206 No abstract available.
Abstract
Background: The combination of male gender, obstructive sleep apnoea (OSA) and obesity magnifies cardiometabolic risk. There has been no systematic study evaluating whether testosterone therapy can improve cardiometabolic health in obese men with OSA by improving body composition, visceral abdominal fat and insulin sensitivity.
Objective: To assess body compositional and cardiometabolic effects of testosterone treatment in obese men with severe OSA.
Design: An 18-week randomised, double-blind, placebo-controlled and parallel group trial in 67 men.
Methods: Participants (age=49 ± 12 years, apnoea hypopnoea index=39.9 ± 17.7 events/h, BMI=31.3 ± 5.2 kg/m(2)) were placed on a hypocaloric diet and received i.m. injections of either 1000 mg testosterone undecanoate (n=33) or placebo (n=34) for 18 weeks. Outcomes were the changes in body composition (total muscle mass, total and abdominal fat, total body dual-energy X-ray absorptiometry and computerised tomography (CT)), weight, insulin sensitivity (homeostasis model assessment), abdominal liver fat (CT), arterial stiffness (pulse wave analysis), resting metabolic rate and respiratory quotient (indirect calorimetry) and blood lipids and metabolic syndrome from baseline to week 18.
Results: After 18 weeks, testosterone treatment increased insulin sensitivity (-1.14 units, 95% confidence interval (95% CI) -2.27 to -0.01, P<0.05), reduced liver fat (0.09 Hounsfield attenuation ratio, 95% CI 0.009 to 0.17, P=0.03) and increased muscle mass (1.6 kg, 95% CI 0.69 to 2.5, P=0.0009) to a greater extent than placebo. Other measures of body composition and regional adiposity as well as the number of participants with metabolic syndrome did not change. Testosterone also decreased arterial stiffness (augmentation index) by 3.2% (95% CI -6.01 to -0.46%, P=0.02) and decreased the respiratory quotient (95% CI -0.04, -0.08 to -0.001, P=0.04) after 18 weeks compared with placebo.
Conclusion: Eighteen weeks of testosterone therapy in obese men with OSA improved several important cardiometabolic parameters but did not differentially reduce overall weight or the metabolic syndrome. Longer term studies are required.
Similar articles
-
Cardiometabolic changes after continuous positive airway pressure for obstructive sleep apnoea: a randomised sham-controlled study.Thorax. 2012 Dec;67(12):1081-9. doi: 10.1136/thoraxjnl-2011-201420. Epub 2012 May 5. Thorax. 2012. PMID: 22561530 Clinical Trial.
-
Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo-controlled trial.Clin Endocrinol (Oxf). 2012 Oct;77(4):599-607. doi: 10.1111/j.1365-2265.2012.04413.x. Clin Endocrinol (Oxf). 2012. PMID: 22512435 Clinical Trial.
-
Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review.Curr Diabetes Rev. 2012 Mar;8(2):131-43. doi: 10.2174/157339912799424573. Curr Diabetes Rev. 2012. PMID: 22268394 Free PMC article. Review.
-
Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity.J Clin Endocrinol Metab. 2007 Mar;92(3):1049-57. doi: 10.1210/jc.2006-2060. Epub 2006 Dec 12. J Clin Endocrinol Metab. 2007. PMID: 17164307 Clinical Trial.
-
Obesity and hormonal factors in sleep and sleep apnea.Med Clin North Am. 1985 Nov;69(6):1265-80. doi: 10.1016/s0025-7125(16)30986-5. Med Clin North Am. 1985. PMID: 3906303 Review.
Cited by
-
Hypogonadism and nonalcoholic fatty liver disease.Endocrine. 2024 May 21. doi: 10.1007/s12020-024-03878-1. Online ahead of print. Endocrine. 2024. PMID: 38771482 Review.
-
Androgen signaling inhibits de novo lipogenesis to alleviate lipid deposition in zebrafish.Zool Res. 2024 Mar 18;45(2):355-366. doi: 10.24272/j.issn.2095-8137.2023.324. Zool Res. 2024. PMID: 38485505 Free PMC article.
-
Association of sex hormones and sex hormone-binding globulin with liver fat in men and women: an observational and Mendelian randomization study.Front Endocrinol (Lausanne). 2023 Oct 13;14:1223162. doi: 10.3389/fendo.2023.1223162. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37900132 Free PMC article.
-
Sleep, testosterone and cortisol balance, and ageing men.Rev Endocr Metab Disord. 2022 Dec;23(6):1323-1339. doi: 10.1007/s11154-022-09755-4. Epub 2022 Sep 24. Rev Endocr Metab Disord. 2022. PMID: 36152143 Free PMC article. Review.
-
Relationship between total testosterone, sex hormone-binding globulin levels and the severity of non-alcoholic fatty liver disease in males: a meta-analysis.Ther Adv Endocrinol Metab. 2022 Jun 24;13:20420188221106879. doi: 10.1177/20420188221106879. eCollection 2022. Ther Adv Endocrinol Metab. 2022. PMID: 35785018 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical